Nexus to build £199m sterile injectable manufacturing facility in US

WCN Editorial Team 15 Jul 2019 NORTH AMERICA BUILDINGS

US-based healthcare company Nexus Pharmaceuticals is planning to build a new sterile injectable manufacturing facility in Pleasant Prairie, Wisconsin, with an estimated investment of $250m (£199.4m).

As part of this effort, Nexus has signed an agreement with Wisconsin’s village Pleasant Prairie for the development of the manufacturing facility.

The 100,000ft² facility will be equipped to support the production and supply of injectable drugs therapeutic in areas such as anaesthesia, oncology, cardiovascular and neurology.

Nexus Pharmaceuticals CEO Mariam Darsot said: “This investment is needed to drive the continued growth for the U.S. pharmaceutical manufacturing industry.

“We would like to thank the Wisconsin Economic Development Corporation, The Milwaukee 7, Kenosha Area Business Alliance and The Village of Pleasant Prairie for their support as we develop our plans for this major expansion project.”

The multi-phase, multi-year project is scheduled for completion in 10 years.

Pleasant Prairie village president Steinbrink said: “Nexus is a remarkable company with excellent jobs, strong growth and high values. I am confident that Nexus will find Prairie Highlands Corporate Park in Pleasant Prairie to be an exceptional location to grow their business.”

Construction on the first phase of the project is scheduled to commence in August 2019 and be completed in 2021. It involves the construction of a three-storey manufacturing facility with an investment of around $85m (£68m).

The production facility will feature an optimised technology, including an advanced isolator system for maximum product protection and sterility.

Additional features of the facility include multiple lyophilisation (freeze-drying) machines to support its production of the current portfolio, as well as generic and specialty injectable drugs.

The company plans to begin commercial production in 2022, subject to approval from the US Food and Drug Administration (FDA) for the facility and manufacturing processes.

Integrated Project Services (IPS) is the designer of the new facility, whereas Turner Construction is the construction management service provider.


Image: Illustration of Nexus’s sterile injectable manufacturing facility in Wisconsin, US. Photo: courtesy of Integrated Project Services (IPS).

With 11 websites and newsletters covering all the key areas within the construction industry, World Construction Industry Network is the leading global construction information resource. READ ABOUT US



World Construction Network | is a product of GlobalData. Copyright © 2021 GlobalData. All rights reserved.